Accounts Receivable, after Allowance for Credit Loss, Current of Outlook Therapeutics, Inc. from 30 Sep 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Outlook Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Sep 2015 to 31 Dec 2025.
  • Outlook Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $114,609.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Outlook Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $114,609 31 Dec 2025 10-Q 17 Feb 2026 2026 Q1
Q3 2025 $1,490,931 30 Sep 2025 10-Q 17 Feb 2026 2026 Q1
Q2 2025 $1,751,422 30 Jun 2025 10-Q 14 Aug 2025 2025 Q3
Q2 2016 $3,670 30 Jun 2016 10-Q 15 Aug 2016 2016 Q3
Q1 2016 $504,857 31 Mar 2016 10-Q 27 Jun 2016 2016 Q2
Q3 2015 $20,000 30 Sep 2015 10-K 29 Dec 2016 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.